ArticlePloS one2025
Chronic central retinal artery occlusion: Clinical manifestations, ocular neovascular complications, and risk of stroke.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Retinal, Vascular, and Choroidal Remodeling After Non-Reperfused Central Retinal Artery Occlusion: A Longitudinal OCT Study.Diagnostics (Basel, Switzerland) · 2026Article
- Simultaneous Bilateral Central Retinal Artery Occlusions: Partial Recovery With Multimodal Therapy.Cureus · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central retinal artery occlusion (CRAO) is a vision-threatening emergency that can lead to chronic ischemic complications. This retrospective cohort study investigated clinical characteristics, neovascular complications, and stroke risk in patients with chronic CRAO defined as the post-acute phase state characterized by FA-confirmed persistent retinal ischemia ≥1 month after acute onset. We reviewed medical records of 570 eyes initially diagnosed with acute non-arteritic CRAO between September 2003 and December 2024, with 289 eyes meeting inclusion criteria. Chronic CRAO was defined as persistent prolonged arm-to-retina or arteriovenous transit times on fluorescein angiography performed >1 month after symptom onset, and further classified as delayed perfusion or nonperfusion based on venous filling patterns. Among 289 patients, 215 eyes (74.4%) had acute CRAO with spontaneous reperfusion, while 74 eyes (25.6%) had chronic CRAO, including 55 eyes (74.3%) with delayed perfusion and 19 eyes (25.7%) with nonperfusion. Chronic CRAO patients were older with higher prevalence of systemic comorbidities. Previous stroke (43.2% vs. 26.0%, p = 0.009) and concurrent stroke (20.3% vs. 12.1%, p = 0.122) were more common in chronic CRAO patients compared to acute CRAO. Neovascularization of the iris occurred exclusively in chronic CRAO (32.4% vs. 0.0%, p < 0.001), with the nonperfusion group showing significantly higher rates of neovascularization of the iris (90% vs. 13%, p < 0.001) and neovascular glaucoma (68% vs. 9%, p < 0.001) compared to delayed perfusion group. Kaplan-Meier analysis revealed earlier onset of neovascularization in nonperfusion cases (median 1.6 months) with a 20-fold increased hazard ratio. Approximately one quarter of acute non-arteritic CRAO patients progress to chronic CRAO, which is associated with increased stroke risk and ocular neovascularization, particularly when retinal arterial nonperfusion persists. These findings emphasize the importance of fluorescein angiography monitoring and systemic evaluation in CRAO management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.